Literature DB >> 25648399

Age-specific differences in influenza virus type and subtype distribution in the 2012/2013 season in 12 European countries.

J Beauté1, P Zucs1, N Korsun2, K Bragstad3, V Enouf4, A Kossyvakis5, A Griškevičius6, C M Olinger7, A Meijer8, R Guiomar9, K Prosenc10, E Staroňová11, C Delgado12, M Brytting13, E Broberg1.   

Abstract

The epidemiology of seasonal influenza is influenced by age. During the influenza season, the European Influenza Surveillance Network (EISN) reports weekly virological and syndromic surveillance data [mostly influenza-like illness (ILI)] based on national networks of sentinel primary-care providers. Aggregated numbers by age group are available for ILI, but not linked to the virological data. At the end of the influenza season 2012/2013, all EISN laboratories were invited to submit a subset of their virological data for this season, including information on age. The analysis by age group suggests that the overall distribution of circulating (sub)types may mask substantial differences between age groups. Thus, in cases aged 5-14 years, 75% tested positive for influenza B virus whereas all other age groups had an even distribution of influenza A and B viruses. This means that the intepretation of syndromic surveillance data without age group-specific virological data may be misleading. Surveillance at the European level would benefit from the reporting of age-specific influenza data.

Entities:  

Keywords:  Influenza; influenza (seasonal); respiratory infections; surveillance; surveillance system

Mesh:

Year:  2015        PMID: 25648399      PMCID: PMC4595855          DOI: 10.1017/S0950268814003422

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


INTRODUCTION

Influenza is an acute respiratory tract infection caused by influenza viruses. The most commonly involved genera are influenza viruses A and B [1]. Influenza A viruses are further divided in subtypes – mainly A(H1)pdm09 and A(H3) in recent influenza seasons – and influenza B viruses are classified in lineages. In the Northern hemisphere, these viruses are responsible for the yearly influenza epidemic that infects a substantial proportion (~20%) of the population during winter [2]. Although most cases of infection will be asymptomatic or suffer a relatively mild illness, the large numbers of infected inviduals result in large numbers of severe cases and deaths every season [1, 3]. The epidemiology of seasonal influenza is influenced by age on different levels. First, the highest notification rates are usually reported in younger age groups [4, 5]. Second, the clinical presentation of the disease varies across age groups [1, 2]. The typical sudden onset of fever accompanied by headache, malaise, myalgia and upper respiratory symptoms seen in adults and adolescents is not as often observed in children or elderly people [1]. Third, adults aged ⩾65 years are more at risk for complications, hospitalizations and death [6, 7]. Fourth, there is some evidence that some age groups play a more prominent role in transmitting the virus. It has been suggested that children may play an important role in household transmission [8], that they may even be a driver for the spread of influenza epidemics, although the magnitude of children's contribution remains controversial [9]. Finally, immunity against influenza is likely to differ across age groups because of different previous exposure to influenza viruses as highlighted during the 2009 pandemic when elderly people were less affected [10], different vaccination policies [11] and different vaccine effectiveness [12]. Seasonal vaccination is recommended for risk groups, including the elderly, in most European Union/European Economic Area (EU/EEA) countries, but children are included only in a minority of Member States [11]. Low vaccine effectiveness has been reported in recent influenza seasons, especially in older age groups [12]. Circulating influenza strains influence the age distribution of infection, disease and severe outcomes of each season. A recent study carried out in the UK showed that the risk of symptomatic disease tends to decrease with age for influenza A and children have higher rates during influenza B waves [2]. The A(H1)pdm09 subtype appears to have infected children first with adolescents and young adults being significantly affected only in the second wave of the 2009 pandemic [2]. Some influenza subtypes, such as influenza A(H3N2), could be associated with a higher severity, especially in older age groups [13, 14] and in long-term healthcare facilities [15]. Influenza types and subtypes may have an impact on the age distribution of hospitalized cases [16, 17], but this is not well documented in primary care. Influenza surveillance in Europe, with the integration of clinical and virological data as its cornerstone, has a long history [18]. Virological and syndromic surveillance data [mostly influenza-like illness (ILI) but also acute respiratory illness (ARI)] are collected through national networks of sentinel primary-care providers. Aggregated numbers by age group are available for ILI/ARI, but not for the virological data. The objectives of this study were to (a) describe age-specific differences in the distribution of influenza viruses for the influenza season 2012/2013, and (b) compare age distributions of influenza-positive sentinel cases and ILI/ARI cases.

METHODS

The surveillance of influenza in Europe is performed by the European Influenza Surveillance Network (EISN) under the coordination of the European Centre for Disease Prevention and Control (ECDC) [16]. At the end of the influenza season 2012/2013, all EISN laboratories were invited to submit a subset of their data for this season. The variables were limited to reporting week, patient age and influenza type and subtype. For the purpose of this analysis, both dual influenza infections and infections with influenza virus type C were excluded. ILI and ARI data for the 2012/2013 season were obtained from the European Surveillance System (TESSy) database hosted at ECDC. EISN members are recommended to use the EU case definitions for ILI and ARI [19]. If both ILI and ARI were available, ILI was preferred. The age groups analysed were 0–4, 5–14, 15–64 and ⩾65 years. For the description of the influenza season 2012/2013, pooled virological data was extracted from TESSy for the 29 EISN countries. Age distributions of influenza-positive sentinel cases and ILI or ARI notifications were compared at country level. Influenza type and subtype distribution between age groups was compared at European level. In countries with age-specific specimen denominator data, the proportion of influenza-positive specimens was compared across age groups at country level. Overall dominance of virus type and subtype was compared with age-specific dominance at country level. Dominance was defined as a proportion of an influenza virus type or subtype ⩾60%. Testing of differences was done with χ2 or Fisher's exact tests with the level of significance set at P < 0·05.

RESULTS

Participating countries and available data

Twelve of 29 EISN Member States reported age-specific data for 7890 positive specimens during the reporting period from week 40/2012 to week 20/2013. Most participating countries reported ILI cases, but France and Bulgaria only reported ARI (Table 1). In nine countries, ILI/ARI data were available by age group (Table 1). Nine countries were able to provide denominators with the number of tests performed (Table 2). Twenty-one co-infections and two cases with a positive test for influenza virus type C were excluded. Information on age was not available for 18 cases from six countries. Finally, 7849 cases (99%) were kept in the analysis.
Table 1.

Age distribution of influenza-positive sentinel specimens and ILI/ARI cases by country, 12 European Union countries, influenza season 2012/2013

Reporting countryType of surveillanceProportion of specimens and cases by age group, total number of specimens and casesComparison between age distributions in confirmed influenza and ILI/ARI cases (P values)
0–4 yr (%)5–14 yr (%)15–64 yr (%)⩾65 yr (%)N
BulgariaSpecimens184435379<0·01
ARI cases212450599 565
DenmarkSpecimens613756171<0·01
ILI cases131859107358
FranceSpecimens26274252602<0·01
ARI cases3424357162 536
GreeceSpecimens114436988n.a.*
ILI cases
LithuaniaSpecimens1027549367n.a.
ILI cases
LuxembourgSpecimens1630504353n.a.
ILI cases
The NetherlandsSpecimens516709387<0·01
ILI cases131059182149
PortugalSpecimens4137671930·67
ILI cases510768221
SlovakiaSpecimens932562133<0·05
ILI cases1828486225 559
SloveniaSpecimens1538452338<0·01
ILI cases736552541
SpainSpecimens12325342651<0·01
ILI cases173445517 741
SwedenSpecimens5147474870·62
ILI cases5137391302

ILI, Influenza-like illness; ARI, acute respiratory illness.

Comparisons were not applicable (n.a.) where syndromic cases were not reported by age group.

Table 2.

Age distribution of the proportion of influenza-positive specimens by country, nine European Union countries with age-specific specimen denominator data, influenza season 2012/2013

Reporting countryProportion of influenza-positive specimens/tested specimens by age groupComparison between positivity rates (P values)
0–4 yr (%)5–14 yr (%)15–64 yr (%)⩾65 yr (%)Total (%)
Bulgaria14/94 (15)35/141 (25)28/164 (17)2/21 (10)79/420 (19)0·15
France668/1767 (38)700/1140 (67)1095/2203 (50)139/298 (47)2602/5 408 (48)<0·01
Greece10/33 (30)39/85 (46)32/67 (48)7/16 (50)88/201 (44)0·39
The Netherlands21/130 (16)60/122 (49)271/776 (35)35/148 (24)387/1176 (33)<0·01
Portugal7/14 (50)26/45 (58)149/205 (73)11/61 (18)193/325 (59)<0·01
Slovakia12/19 (63)43/72 (60)75/106 (71)3/7 (43)133/204 (66)0·25
Slovenia49/158 (31)128/194 (66)153/242 (63)8/11 (73)338/605 (56)<0·01
Spain317/773 (41)836/1352 (62)1401/2562 (55)97/256 (38)2651/4943 (54)<0·01
Sweden26/101 (26)66/121 (55)360/1217 (30)35/209 (17)487/1648 (30)<0·01
Age distribution of influenza-positive sentinel specimens and ILI/ARI cases by country, 12 European Union countries, influenza season 2012/2013 ILI, Influenza-like illness; ARI, acute respiratory illness. Comparisons were not applicable (n.a.) where syndromic cases were not reported by age group. Age distribution of the proportion of influenza-positive specimens by country, nine European Union countries with age-specific specimen denominator data, influenza season 2012/2013

Influenza season 2012/2013

At the EU/EEA level, the 2012/2013 influenza season started about week 49/2012, had a prolonged peak between week 4/2013 and week 8/2013 and lasted until week 16/2013 (Fig. 1). The epidemic peak occurred in week 6/2013, when 1632 of the 2607 sentinel swabs collected (63%) tested positive for influenza virus in 29 countries. From week 40/2012 to week 20/2013, these 29 countries tested 33 819 specimens, of which 15 744 (47%) tested positive for influenza virus.
Fig. 1.

Number of influenza-positive sentinel specimens and percentage* by type, (sub)type and week. (a) European Union/European Economic Area (EU/EEA), (b) 12 EU countries†, week 40/2012 to week 20/2013. (* Percentages are displayed in weeks where at least 50 influenza-positive specimens were reported; † Bulgaria, Denmark, France, Greece, Lithuania, Luxembourg, The Netherlands, Portugal, Slovakia, Slovenia, Spain, and Sweden.

Number of influenza-positive sentinel specimens and percentage* by type, (sub)type and week. (a) European Union/European Economic Area (EU/EEA), (b) 12 EU countries†, week 40/2012 to week 20/2013. (* Percentages are displayed in weeks where at least 50 influenza-positive specimens were reported; † Bulgaria, Denmark, France, Greece, Lithuania, Luxembourg, The Netherlands, Portugal, Slovakia, Slovenia, Spain, and Sweden. Similarly, in the 12 participating countries, the 2012/2013 influenza season started about week 49/2012, had a prolonged peak between week 4/2013 and week 8/2013 and lasted until week 16/2013 (Fig. 1). In week 7/2013, at the peak of the epidemic, 892 of the 1336 sentinel swabs collected (67%) tested positive for influenza virus. From week 40/2012 to week 20/2013, the 12 participating countries tested 16 508 specimens, of which 8076 (49%) tested positive for influenza virus. In the 12 participating countries as well as in all EU/EEA countries, the distribution of influenza virus (sub)types over the season showed an overall predominance of influenza B virus with an increase over time (~70% of influenza-positive specimens were B virus for week 13/2013). Influenza A(H1)pdm09 virus peaked in week 2/2013 when it accounted for 40% of all influenza-positive specimens while the proportion of A(H3) virus was near or below 20% for most of the season (Fig. 1, ).

Influenza detections and clinical diagnoses by age group

Of the nine countries for which ILI/ARI data were available by age group, seven had an age distribution based on influenza-positive sentinel specimens that was statistically different from the one observed for ILI/ARI (Table 1). With the exception of Slovenia, the proportion of influenza-positive specimens in the ⩾65 years age group was systematically lower than the proportion of ILI/ARI. The proportion of tested specimens by age group was statistically different from the one observed for ILI/ARI in all eight countries for which both number of tested specimens and ILI/ARI data were available by age group. However, in all these eight countries the 15–64 years age group accounted for both the highest number of ILI/ARI and tested specimens. The proportion of influenza-positive specimens significantly differed accross age groups in six of the nine countries that provided age-specific specimen denominator data (Table 2). In some countries, substantial differences were observed as for The Netherlands, where 16% of specimens were positive in the 0–4 years group compared to 49% in the 5–14 years group.

Distribution of influenza virus type and subtype by age group

Of the 7849 positive specimens reported with information on age, 1227 (16%) were from the 0–4 years age group, 2161 (28%) from 5–14 years, 4067 (52%) from 15–64 years and 394 (5%) from cases aged ⩾65 years. In cases aged 5–14 years, 75% tested positive for influenza B virus whereas all other age groups had an even distribution of influenza A and B viruses (Fig. 2). Of the influenza A viruses subtyped, A(H1)pdm09 viruses dominated over A(H3) viruses in all cases up to age 64 years (68% vs. 32% overall) whereas in those aged ⩾65 years, A(H3) viruses dominated (65% vs. 35%). Overall, the distribution of the virus types and subtypes were significantly different in age groups (P < 0·0001).
Fig. 2.

Influenza virus type and subtype distribution by age group, 12 European Union countries, influenza season 2012/2013.

Influenza virus type and subtype distribution by age group, 12 European Union countries, influenza season 2012/2013. In most countries, dominant virus (sub)type varied accross age groups (Tables 3 and 4). Of note, a predominance of influenza B virus was observed in most countries (10/12) in the 5–14 years age group while no clear pattern emerged in the other age groups. Spain was the only country where predominance of the same type was observed in all age groups.
Table 3.

Age distribution of influenza-positive specimens by influenza virus (sub)type and country, 12 European Union countries, influenza season 2012/2013

Reporting countryVirus (sub)type0–4 yr (%)5–14 yr (%)15–64 yr (%)⩾65 yr (%)Total (%)
BulgariaA(H1)pdm096 (43)5 (14)8 (29)1 (50)20 (25)
A(H3)03 (9)3 (11)06 (8)
A unsubtyped02 (6)002 (3)
B8 (57)25 (71)17 (61)1 (50)51 (65)
Total14 (100)35 (100)28 (100)2 (100)79 (100)
DenmarkA(H1)pdm091 (10)011 (9)012 (7)
A(H3)6 (60)5 (23)47 (36)5 (50)63 (37)
A unsubtyped00000
B3 (30)17 (77)71 (55)5 (50)96 (56)
Total10 (100)22 (100)129 (100)10 (100)171 (100)
FranceA(H1)pdm09173 (26)95 (14)322 (29)17 (12)607 (23)
A(H3)122 (18)99 (14)225 (21)56 (40)502 (19)
A unsubtyped14 (2)9 (1)45 (4)4 (3)72 (3)
B359 (54)497 (71)503 (46)62 (45)1421 (55)
Total668 (100)700 (100)1095 (100)139 (100)2602 (100)
GreeceA(H1)pdm094 (40)8 (21)16 (50)1 (14)29 (33)
A(H3)6 (60)28 (72)13 (41)6 (86)53 (60)
A unsubtyped00000
B03 (8)3 (9)06 (7)
Total10 (100)39 (100)32 (100)7 (100)88 (100)
LithuaniaA(H1)pdm0923 (61)31 (31)99 (50)6 (18)159 (43)
A(H3)5 (13)11 (11)5 (3)3 (9)24 (7)
A unsubtyped7 (18)14 (14)49 (25)5 (15)75 (20)
B3 (8)43 (43)44 (22)19 (58)109 (30)
Total38 (100)99 (100)197 (100)33 (100)367 (100)
LuxembourgA(H1)pdm0921 (38)26 (24)83 (47)1 (7)131 (37)
A(H3)1 (2)1 (1)6 (3)1 (7)9 (3)
A unsubtyped12 (22)14 (13)27 (15)9 (64)62 (18)
B21 (38)66 (62)61 (34)3 (21)151 (43)
Total55 (100)107 (100)177 (100)14 (100)353 (100)
The NetherlandsA(H1)pdm096 (29)4 (7)78 (298 (23)96 (25)
A(H3)11 (52)12 (20)54 (20)16 (46)93 (24)
A unsubtyped00000
B4 (19)44 (73)139 (51)11 (31)198 (51)
Total21 (100)60 (100)271 (100)35 (100)387 (100)
PortugalA(H1)pdm091 (14)6 (23)87 (58)7 (64)101 (52)
A(H3)1 (14)1 (4)4 (3)1 (9)7 (4)
A unsubtyped00000
B5 (71)19 (73)58 (39)3 (27)85 (44)
Total7 (100)26 (100)149 (100)11 (100)193 (100)
SlovakiaA(H1)pdm096 (50)5 (12)18 (24)029 (22)
A(H3)1 (8)5 (12)13 (17)1 (33)20 (15)
A unsubtyped2 (17)2 (5)7 (9)011 (8)
B3 (25)31 (72)37 (49)2 (67)73 (55)
Total12 (100)43 (100)75 (100)3 (100)133 (100)
SloveniaA(H1)pdm0922 (45)24 (19)82 (54)5 (63)133 (39)
A(H3)3 (6)6 (5)12 (8)021 (6)
A unsubtyped03 (2)003 (1)
B24 (49)95 (74)59 (39)3 (38)181 (54)
Total49 (100)128 (100)153 (100)8 (100)338 (100)
SpainA(H1)pdm0958 (18)78 (9)371 (26)11 (11)518 (20)
A(H3)10 (3)17 (2)58 (4)12 (12)97 (4)
A unsubtyped6 (2)8 (1)11 (1)2 (2)27 (1)
B243 (77)733 (88)96 16972742009 (76)
Total317 (100)836 (100)1 401 10097 1002 651 100
SwedenA(H1)pdm0911 (42)11 (17)151 (42)3 (9)176 (36)
A(H3)11 (42)12 (18)89 (25)13 (38)125 (26)
A unsubtyped1 (4)015 (4)2 (6)18 (4)
B3 (12)43 (65)106 (29)16 (47)168 (34)
Total26 (100)66 (100)361 (100)34 (100)487 (100)
TotalA(H1)pdm09332 (27)293 (14)1326 (33)60 (15)2011 (26)
A(H3)177 (14)200 (9)529 (13)114 (29)1020 (13)
A unsubtyped42 (3)52 (2)154 (4)22 (6)270 (3)
B676 (55)1616 (752059 (51)197 (50)4548 (58)
Total1227 (100)2161 (100)4068 (100)393 (100)7849 (100)
Table 4.

Dominant influenza virus type or subtype by age group and country, 12 European Union countries, influenza season 2012/2013

Reporting countryOverall dominant* type or subtypeDominant type or subtype by age group
0–4 yr5–14 yr15–64 yr⩾65 yr
BulgariaBNoneBBNone
DenmarkNoneA(H3)BNoneNone
FranceNoneNoneBNoneNone
GreeceA(H3)A(H3)A(H3)NoneA(H3)
LithuaniaNoneA(H1)pdm09NoneNoneNone
LuxembourgNoneNoneBNoneNone
NetherlandsNoneNoneBNoneNone
PortugalNoneBBNoneA(H1)pdm09
SlovakiaNoneNoneBNoneB
SloveniaNoneNoneBNoneA(H1)pdm09
SpainBBBBB
SwedenNoneNoneBNoneNone

Dominance was defined as ⩾60%.

Age distribution of influenza-positive specimens by influenza virus (sub)type and country, 12 European Union countries, influenza season 2012/2013 Dominant influenza virus type or subtype by age group and country, 12 European Union countries, influenza season 2012/2013 Dominance was defined as ⩾60%.

DISCUSSION

In Europe, the influenza season 2012/2013 was characterized by a co-circulation of three influenza virus types and subtypes, offering a good opportunity to determine whether the distribution of types and subtypes differs accross age groups [20]. Our findings suggest that the overall distribution of types and subtypes may mask substantial differences between age groups. Thus, A(H3) – a subtype frequently associated with a higher morbidity than the previous seasonal A(H1) and B viruses [13, 14] – was especially prevalent in cases aged ⩾65 years. Conversely, influenza B virus predominated in children aged 5–14 years, which supports prevous findings from Germany and the UK [2, 21]. The remaining age groups experienced a more evenly distributed mixed season of A and B viruses. Of note, country-specific profiles of dominance and age-specific proportions of influenza virus types and subtypes were markedly different. Age-specific influenza surveillance data should be interpreted with caution. In most countries, the age distribution of ILI/ARI differed from the age distribution of cases with confirmed influenza. Our findings suggest that sampling strategies may have slighly differed accross age groups. The relative overrepresentation of positive specimens collected in adults aged 15–64 years may be suggestive of differences in health-seeking behaviour. Since both clinical and virological indicators are collected through the same sentinel scheme, there are at least two additional possible explanations. First, the contribution of other respiratory pathogens differs across age groups. Besides influenza A and B viruses, parainfluenza virus and respiratory syncytial virus (RSV) contribute to ILI estimates [22]. Specifically, the burden of RSV in children aged <5 years is now well established [23] and there is increasing evidence suggesting that it might also cause a substantial amount of illness in the elderly [24]. Second, the varying proportion of positive specimens across age group could be explained by differential virus shedding by age or virus (sub)type. A recent study carried out in Germany could not find any evidence supporting this latter hypothesis [25]. Regardless of the reason why age distributions differs between clinical and confirmed cases, this study reminds us that ILI/ARI rates by age group should be interpreted very cautiously in the absence of virological data. In countries where ILI/ARI data are not available by age group, influenza surveillance would therefore benefit from collecting virological data by age group. If confirmed over several influenza seasons, these findings may have important implications for vaccination policies. The first objective of influenza vaccination is to prevent severe disease and death. It is now well established that elderly people have the highest mortality risk and therefore constitute a well-identified risk group [26]. Previous studies have suggested that the extension of vaccine coverage to younger age groups would increase protection in the elderly [27, 28]. In seasons with different dominating strains accross age groups, the impact of such an extension may well be limited. The relatively low number of specimens collected in some countries was an important limitation of this study, as some statistical analyses were not possible. For the same reason, it was not possible to look at the dynamics of transmission across age groups. In addition, such analysis would probably have to include several seasons. This study also underlined the need to document the sampling strategies in EISN countries as the selection of patients to be swabbed may not be systematic in all surveillance schemes. The overall distribution of influenza viruses in the 29 EISN Member States under surveillance was similar to the one observed in the 12 countries participating in this study, suggesting that our findings may also be valid for the rest of the EISN Member States.

CONCLUSION

This study demonstrates the added value of including age group data in routine virological influenza surveillance because they provide a better indication of the age-specific distribution of influenza infection and its causative virus types and subtypes than pooled virological data or age-specific ILI/ARI rates. With better estimates of the burden of influenza in different age groups, it would help identify target groups for preventive measures. Last, similar data collection in the coming years could help improve our understanding of the dynamics and transmission of influenza. Such data would not necessary have to be collected every week, but could be collected once after every season. This would also constitute a step towards a more integrated clinical and virological influenza surveillance.
  27 in total

1.  Overrepresentation of influenza A(H1N1)pdm09 virus among severe influenza cases in the 2011/12 season in four European countries.

Authors:  J Beauté; E Broberg; F Plata; I Bonmarin; J O Donnell; C Delgado; N Boddington; R Snacken
Journal:  Euro Surveill       Date:  2012-03-01

2.  Variation in adult vaccination policies across Europe: an overview from VENICE network on vaccine recommendations, funding and coverage.

Authors:  Elisabeth E Kanitz; Lauren A Wu; Cristina Giambi; Raymond A Strikas; Daniel Levy-Bruhl; Pawel Stefanoff; Jolita Mereckiene; Eva Appelgren; Fortunato D'Ancona
Journal:  Vaccine       Date:  2012-06-18       Impact factor: 3.641

Review 3.  Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence.

Authors:  Rachel Jordan; Martin Connock; Esther Albon; Anne Fry-Smith; Babatunde Olowokure; Jeremy Hawker; Amanda Burls
Journal:  Vaccine       Date:  2005-09-26       Impact factor: 3.641

4.  Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2013-09-20

Review 5.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.

Authors:  Harish Nair; D James Nokes; Bradford D Gessner; Mukesh Dherani; Shabir A Madhi; Rosalyn J Singleton; Katherine L O'Brien; Anna Roca; Peter F Wright; Nigel Bruce; Aruna Chandran; Evropi Theodoratou; Agustinus Sutanto; Endang R Sedyaningsih; Mwanajuma Ngama; Patrick K Munywoki; Cissy Kartasasmita; Eric A F Simões; Igor Rudan; Martin W Weber; Harry Campbell
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

6.  Risk factors of influenza transmission in households.

Authors:  Cécile Viboud; Pierre-Yves Boëlle; Simon Cauchemez; Audrey Lavenu; Alain-Jacques Valleron; Antoine Flahault; Fabrice Carrat
Journal:  Br J Gen Pract       Date:  2004-09       Impact factor: 5.386

Review 7.  Burden of paediatric influenza in Western Europe: a systematic review.

Authors:  Evgeniya N Antonova; Catherine E Rycroft; Christopher S Ambrose; Terho Heikkinen; Nicola Principi
Journal:  BMC Public Health       Date:  2012-11-12       Impact factor: 3.295

8.  Age-specific differences in influenza A epidemic curves: do children drive the spread of influenza epidemics?

Authors:  Dena Schanzer; Julie Vachon; Louise Pelletier
Journal:  Am J Epidemiol       Date:  2011-05-20       Impact factor: 4.897

9.  Contribution of respiratory pathogens to influenza-like illness consultations.

Authors:  K Bollaerts; J Antoine; V Van Casteren; G Ducoffre; N Hens; S Quoilin
Journal:  Epidemiol Infect       Date:  2012-12-06       Impact factor: 2.451

Review 10.  Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis.

Authors:  Dominik Mertz; Tae Hyong Kim; Jennie Johnstone; Po-Po Lam; Michelle Science; Stefan P Kuster; Shaza A Fadel; Dat Tran; Eduardo Fernandez; Neera Bhatnagar; Mark Loeb
Journal:  BMJ       Date:  2013-08-23
View more
  18 in total

1.  [The universal influenza vaccination in children with Vaxigrip Tetra® in Italy: an evaluation of Health Technology Assessment].

Authors:  Sara Boccalini; Angela Bechini; Maddalena Innocenti; Gino Sartor; Federico Manzi; Paolo Bonanni; Donatella Panatto; Piero Luigi Lai; Francesca Zangrillo; Emanuela Rizzitelli; Mariasilvia Iovine; Daniela Amicizia; Chiara Bini; Andrea Marcellusi; Francesco Saverio Mennini; Alessandro Rinaldi; Francesca Trippi; Anna Maria Ferriero; Giovanni Checcucci Lisi
Journal:  J Prev Med Hyg       Date:  2018-05-30

2.  Illness absenteeism rates in primary and secondary schools in 2013-2014 in England: was there any impact of vaccinating children of primary-school age against influenza?

Authors:  H K Green; N Brousseau; N Andrews; L Selby; R Pebody
Journal:  Epidemiol Infect       Date:  2016-09-09       Impact factor: 4.434

3.  Improving influenza virological surveillance in Europe: strain-based reporting of antigenic and genetic characterisation data, 11 European countries, influenza season 2013/14.

Authors:  Eeva Broberg; Olav Hungnes; Brunhilde Schweiger; Katarina Prosenc; Rod Daniels; Raquel Guiomar; Niina Ikonen; Athanasios Kossyvakis; Francisco Pozo; Simona Puzelli; Isabelle Thomas; Allison Waters; Åsa Wiman; Adam Meijer
Journal:  Euro Surveill       Date:  2016-10-13

4.  Performance of influenza case definitions for influenza community surveillance: based on the French influenza surveillance network GROG, 2009-2014.

Authors:  Jean-Sebastien Casalegno; Daniel Eibach; Martine Valette; Vincent Enouf; Isabelle Daviaud; Sylvie Behillil; Astrid Vabret; Jean Claude Soulary; Mehdi Benchaib; Jean Marie Cohen; Sylvie van der Werf; Anne Mosnier; Bruno Lina
Journal:  Euro Surveill       Date:  2017-04-06

5.  Antigenic and genetic characterization of influenza viruses circulating in Bulgaria during the 2015/2016 season.

Authors:  Neli Korsun; Svetla Angelova; Viki Gregory; Rodney Daniels; Irina Georgieva; John McCauley
Journal:  Infect Genet Evol       Date:  2017-01-27       Impact factor: 3.342

6.  Deploying digital health data to optimize influenza surveillance at national and local scales.

Authors:  Elizabeth C Lee; Ali Arab; Sandra M Goldlust; Cécile Viboud; Bryan T Grenfell; Shweta Bansal
Journal:  PLoS Comput Biol       Date:  2018-03-07       Impact factor: 4.475

7.  Heterogeneous estimates of influenza virus types A and B in the elderly: Results of a meta-regression analysis.

Authors:  Donatella Panatto; Alessio Signori; Piero L Lai; Roberto Gasparini; Daniela Amicizia
Journal:  Influenza Other Respir Viruses       Date:  2018-03-23       Impact factor: 4.380

8.  Earliest infections predict the age distribution of seasonal influenza A cases.

Authors:  Philip Arevalo; Huong Q McLean; Edward A Belongia; Sarah Cobey
Journal:  Elife       Date:  2020-07-07       Impact factor: 8.140

9.  Evaluating oseltamivir prescriptions in Centers for Medicare and Medicaid Services medical claims records as an indicator of seasonal influenza in the United States.

Authors:  F Scott Dahlgren; David K Shay; Hector S Izurieta; Richard A Forshee; Michael Wernecke; Yoganand Chillarige; Yun Lu; Jeffrey A Kelman; Carrie Reed
Journal:  Influenza Other Respir Viruses       Date:  2018-03-25       Impact factor: 4.380

10.  A paediatric influenza update 100 years after the Skyros island Spanish flu outbreak.

Authors:  Ioannis N Mammas; Maria Theodoridou; Prakash Thiagarajan; Angeliki Melidou; Georgia Papaioannou; Paraskevi Korovessi; Chryssie Koutsaftiki; Alexia Papatheodoropoulou; Marcos Calachanis; Tina Dalianis; Demetrios A Spandidos
Journal:  Exp Ther Med       Date:  2019-04-22       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.